Category: Knee deformation

Gift establishes the Sala Elbaum Pediatric Research Scholars Program and the Sala Elbaum Fellowship Endowment Fund.

NEW YORK , Oct. 30, 2023 /PRNewswire/ — NYU Langone Health’s Department of Pediatrics has received $9.8 million from Trudy Elbaum Gottesman and Robert W. Gottesman, founders of the Sala Institute for Child and Family Centered Care, which has been operating since 2013 profoundly influenced excellence in clinical care at NYU Langone’s Hassenfeld Children’s Hospital.

“We are proud to support innovations in pediatric research and the career growth of physician-scientists,” said Trudy Elbaum Gottesman. “Our commitment is unwavering and focused on improving outcomes for children everywhere.”

The Gottesmans’ recent funding will advance innovation in pediatric research, fuel the career development of gifted pediatrician-scientists, prepare pediatric fellows for life-changing careers, and play a critical role in advancing the understanding, prevention, diagnosis, and treatment of childhood diseases. diseases.

“Providing exceptional care means understanding the unique needs of the patients we see at NYU Langone Health – and often no patient is more vulnerable or resilient than a child,” said Robert I. Grossman, MD, dean of NYU Grossman School of Medicine and CEO of NYU Langone Health. “We are fortunate to have supporters like the Gottesmans, who know this so well and are deeply committed to ensuring that Hassenfeld Children’s Hospital, through the Sala Institute, remains the best place for every parent to care for their child to search. Their latest gift will allow us to continue advancing research, fellowship training and the next generation of pediatricians.”

Promote clinical research that enables pediatricians to better manage children’s health

One of the key initiatives supported by Gottesmans’ most recent donation is the establishment of the Sala Elbaum Pediatric Research Scholars Program. To meet the global need for more pediatric physician-scientists, the program provides early career physicians with support and protected time for an intensive, guided career development experience in biomedical, behavioral or clinical research.

“This type of formalized program is critical to improving research in pediatric health care to ensure progress in the field overall,” said Catherine S. Manno, MD, Pat and John Rosenwald Professor of Pediatrics and chair of the pediatrics department. “The program will strengthen our ability to attract, grow and retain the most talented future leaders in science and clinical care, both from within and across the country at NYU Langone Health and Hassenfeld Children’s Hospital community.”

The first two Sala Elbaum scientists are Carol Duh-Leong, MD, general pediatrician at Hassenfeld Children’s Hospital, and Kirsty Hillier, MD, pediatric hematology-oncology specialist at Stephen D. Hassenfeld Children’s Center for Cancer and Blood Disorders.

Over the course of four years, Sala Elbaum Scholars will be supported and trained through this program, and upon completion they will continue to conduct their research independently and competitively through external grants.

Training the next generation of pediatrician leaders

In addition, the Gottesmans’ generosity has created the Sala Elbaum Fellowship Endowment Fund, which will ensure the longevity of a rigorous and competitive fellowship program in the Department of Pediatrics. The Department of Pediatrics recruits some of the nation’s most promising young physicians and trains a full roster of fellows in the diagnosis and care of children with complex and chronic conditions. In recognition of Gottesmans’ gift, two fellows from the Department of Pediatrics will be named Sala Elbaum Fellows in major pediatric subspecialties.

Pediatric subspecialists require an additional two to three years of fellowship training beyond the four years of medical school and three years of residency required to become a general pediatrician.

“Pediatric specialists are the only physicians uniquely qualified to treat many children with complex conditions,” said Dr. Manno. “This fund will help us continue to provide top-notch training for our pediatric fellows, ensuring more pediatricians have deep experience in child- and family-centered care.”

About the Gottesmans

Trudy Elbaum Gottesman and Robert Gottesman are fierce advocates for children’s health and have helped NYU Langone achieve many milestones in pediatric care. Ms. Gottesman has been a trustee of NYU Langone since 2013. She helped found KiDS of NYU Langone in 1991 and currently serves as chair of Sala Circle, a community of supporters who work together to advance the health and well-being of children at Hassenfeld Children’s Hospital. past. Mr. Gottesman is executive chairman, senior managing director, portfolio manager and former CEO of First Manhattan. The Gottesmans helped found and expand the Sala Institute for Child and Family Centered Care – named after Trudy’s late mother, Sala Bierman Elbaum, a Holocaust survivor – to ensure that children and families at Hassenfeld Children’s Hospital can benefit of support services and resilience programs tailored to their needs.

Visit NYU Langone Giving for more information or to make a donation to the Sala Institute to support children’s health.

Media questions

Katie Ullman
Phone: 646-483-3984
Kathryn.Ullman@NYUlangone.org

SOURCE NYU Langone Health System; Hassenfeld Children’s Hospital at NYU Langone

CARLSBAD, California, October 27, 2023–(BUSINESS WIRE)–Alphatec Holdings, Inc. (“ATEC”) (NASDAQ: ATEC), a provider of innovative solutions aimed at revolutionizing the approach to spine surgery, today announced the closing of its previously announced underwritten public offering of 14,300,000 shares of its common stock at a public offering price of $ 10.50 per share.

Morgan Stanley, TD Cowen, Barclays and Stifel acted as joint book-running managers on the offering.

ATEC received gross proceeds of $150,150,000 from the offering.

The shares of common stock were offered pursuant to a registration statement on Form S-3 (File No. 333-271336) previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”). The offering was made by means of a prospectus supplement and the accompanying prospectus. A preliminary prospectus supplement, a final prospectus supplement and a companion prospectus relating to the offering have previously been filed with the SEC and are available on the SEC’s website at www.sec.gov. The preliminary prospectus supplement, the final prospectus supplement and the accompanying base prospectus are available on the SEC’s website and may also be obtained from Morgan Stanley, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; Cowen and Company, LLC, 599 Lexington Avenue, New York, New York 10022, by telephone at (833) 297-2926 or by email at prospectus_ecm@cowen.com; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at 1-888-603-5847 or by email at barclaysprospectus@broadridge.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About ATEC

ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging SAS and SafeOp Surgical, Inc., is a medical device company committed to revolutionizing the approach to spine surgery through clinical differentiation. ATEC’s Organic Innovation Machine™ is focused on developing new approaches that integrate seamlessly with the company’s growing AlphaInformatiX Platform to better inform surgery and achieve the goals of spine surgery more safely and reproducibly. ATEC’s vision is to be the standard bearer in the spine field.

Contacts

Company contact:
J. Todd King
Finance Director
investorrelations@atecspine.com

Investor/media contact:
Tina Jacobsen, CFA
Investor Relations
(760) 494-6790
investorrelations@atecspine.com

Toronto, Ontario, October 27, 2023 (GLOBE NEWSWIRE) — David Rosenkrantz (“Acquiror”) announces that he has filed an early warning report under National Instrument 62-103 in connection with the acquisition of 2,250,000 voting common shares (“Shares”) and 2,250,000 Share Purchase Warrants (“Warrants”) from Aurora Spine Corporation (the “Company”) for an aggregate amount of CAD$675,000.

On October 19, 2023, the acquirer acquired Shares and Warrants of the Company pursuant to a private placement (the “Private Placement”), which in total resulted in the cumulative acquisition of more than 2% of the outstanding Shares of the Company. , which creates the requirement to submit an early warning report. Immediately prior to the acquisition, the Acquiring party owned 9,625,000 Shares of the Company. The 9,625,000 Shares represented approximately 13.56% of the total number of Shares issued and outstanding prior to the Private Placement. As a result of the acquisition, the Acquirer now beneficially owns 11,875,000 Shares of the Company, which is equal to 15.34% of the outstanding Shares of the Company, resulting in a change of 1.78% in the Acquirer’s share ownership side. If all Warrants were converted, the Acquirer would, directly or indirectly, own or exercise control or direction of approximately 17.73% of the total number of issued and outstanding Shares, which would result in an increase of 4.17% of Share Ownership of the Acquirer on a partially diluted basis.

Although the Acquirer currently has no plans or intentions with respect to the Company’s Shares, depending on market conditions, general economic and industry conditions, trading prices of the Company’s Shares, the Company’s business, financial condition and prospects and/or other relevant factors, The acquirer may develop such plans or intentions in the future and may from time to time acquire additional Shares, dispose of some or all existing or additional Shares or sell the Shares of the Company keep holding.

A copy of the acquirer’s early warning report filing will be available on Aurora Spine Corporation’s SEDAR+ profile at www.sedarplus.ca. The Company’s registered office is located at 1930 Palomar Point Way, Suite 103, Carlsbad, California, 92008 and the acquirer’s address is at Patica Corporation, The Exchange Tower, 130 King St. W., Suite 2210, Toronto, Ontario, M5X 1E4 .

Aurora Spine Corporation

760-424-2004

BALTIMORE , Oct. 26, 2023 /PRNewswire-PRWeb/ — Orthopedic surgeons Marc W. Hungerford, MD, Chief of Orthopedics at Mercy Medical Center, and Philip Neubauer, R.Ph., MD, Orthopedics and Joint Replacement at Mercy, are among the first surgeons in Maryland that offered “smart implant” technology during knee replacement surgeries.

Developed by ZIMMER BIOMET, the Persona IQ^® has a small “smart” stem extension attached to the lower portion of the implant. This stem contains sensors that record patient-specific movement data throughout the day, analyze it overnight and present it for assessment the next day.

“Essentially, it is a joint replacement that uses a prosthesis equipped with a smart device that can monitor the patient’s progress,” said Dr. Hungerford.

Surgeons and care teams can remotely access key postoperative metrics throughout their patient’s surgical journey, allowing them to monitor post-TKA (Total Knee Arthroplasty) activity levels between office visits.

The smart knee implant records relevant gait data, including:

• Functional range of motion of the knee (ROM)
• Qualified step count
• Walking speed
• Cadence
• Traveled distance
• Stride length

The smart knee implants provide a direct view of patient-specific data for at least 10 years, allowing surgeons to monitor their patients’ activity levels between visits. In this way, they can remain connected during the patient’s postoperative total knee arthroplasty care.

Additionally, being able to track their postoperative data can help patients feel more connected throughout their recovery journey, promoting greater patient interaction.

“Thanks to this new technology, there is greater patient involvement and surgeons can remotely monitor a patient’s progress. This means better management of postoperative care,” said Dr. Hungerford.

“With the Persona IQ, as a doctor I can no longer just estimate how well a patient’s joint is working after surgery; I have the data to determine how my patient is really doing,” said Dr. Neubauer.

“Mercy is always looking for ways to improve our patients’ experiences and treatment outcomes,” said Dr. Hungerford, “whether it be an emphasis on pre-surgical education, improvements to surgical pathways or advances in techniques and equipment. The smart implants offer real benefits for post-operative care, and we look forward to sharing them with patients.”

Founded in 1874 by The Sisters of Mercy, Mercy is home to the renowned Weinberg Center for Women’s Health & Medicine and the $400+ million, twenty-story Mary Catherine Bunting Center. Mercy is a university-affiliated teaching hospital and is nationally recognized with Magnet status for nursing excellence and named one of America’s 100 Best Hospitals for Orthopedic Surgery by Healthgrades. For more information about Mercy, visit http://www.mdmercy.com, MDMercyMedia on Facebook and Twitter(X), @MDMercy on Youtube, or call 1-800-MD-Mercy.

Media contact

Dan Collins, Mercy Medical Center, 4103329714, dcollins@mdmercy.com

SOURCE Mercy Medical Center

Orthopedic trabecular fixation screw

This patent release further strengthens Cutting Edge Spine as the market leader in the field of trabecular fixation for orthopedic applications.

MINERAL SPRINGS, NC, October 26, 2023 / OrthoSpineNews / – Cutting Edge Spine (http://www.cuttingedgespine.com), a leader in the organic development and commercialization of “passively smart” spinal technologies, today announced the Notice of issuance of the United States Patent and Trademark Office relating to Patent No. US 11,771,482 B2: IMPLANTS FOR TISSUE FIXATION AND FUSION.

This third patent issue covering trabecular screws for all orthopedic fixations gives Cutting Edge Spine an exceptionally strong position in the market compared to the transformational fixation technology offerings that are trabecular in nature.

“Our patent position gives us the opportunity to freely develop a broad portfolio of patented trabecular fixation devices for all orthopedic applications, while at the same time confidently protecting our current and future market position.” said Randy Roof-President & CEO; Founder of Cutting Edge Spine. “Our first such 510(k) cleared spine system, the T-FIX™3DSI Joint Fusion System, was introduced to the market in late spring of this year and has quickly positioned Cutting Edge Spine as a leader in the fast-growing SI sector. fixation market.”

About the advanced spine
Founded in 2009, Cutting Edge Spine (CES) is a privately held medical device organization headquartered in Mineral Springs, NC. The company is committed to developing and commercializing patented “passive smart” orthopedic technologies that are transformative relative to clinical benefit to the patient, without driving up the cost of care.

Media contact
Randy Dak
Cutting Edge Spine LLC,
1 704-839-1916
r.roof@cuttingedgespine.com, www.cuttingedgespine.com

LinkedIn

SOURCE Cutting Edge Spine, LLC

• The completed transaction includes all cervical and lumbar fusion products, including the STALIF® technology platform
• This acquisition makes Silony an important entry into the American market and significantly strengthens its range of stand-alone cages
• Silony Medical will change its name to “Silony Spine” to underline its focus on spine fusion technology

FRAUENFELD, Switzerland, Oct. 19, 2023 /PRNewswire/ — Silony Medical International AG (the Company), a growing challenger to “big medtech” in the global spinal fusion market, has completed the acquisition of Centinel Spine’s Global Fusion Business. This combines Silony’s Verticale® posterior screw and rod fusion platform, its Roccia® and Favo® Interbody Fusion (IBF) systems with the STALIF® technology platform to deliver a premier occiput-to-sacrum, posterior, lateral and anterior spinal fusion portfolio create for open and minimally invasive spinal fusion cases.

Silony has been active in the US market since late 2018 – with this acquisition, Silony will leverage the Centinel Fusion Portfolio’s great team and distribution network to strengthen its position in the North American spine market and provide best-in-class surgeons and their teams offer spine fusion solutions that provide flexibility and freedom.

In the coming days and months, Silony will change its name to Silony Spine to underline its 100% commitment and focus on technological solutions for spine fusion. At the same time, we will begin a refresh of the STALIF platform to drive further adoption among the spine surgeon community. Shortly afterwards we will launch our next generation of technology instruments.

About Silony Medical, soon Silony Spine

Founded in 2013 by the internationally renowned hospital group Schön Clinic in Germany, Silony Spine is a market disruptor that aims to change the status quo of how product manufacturers collaborate with hospital systems. Silony Spine manages and designs spine hardware and devices that provide surgeons and hospitals with high-quality product solutions that are highly compatible with assistive technologies.

For more information, please visit the company’s website at www.silonyspine.com or contact:

Silony Medical International AG

Constantine Schön
Director
Bahnhofplatz 76a, 8500 Frauenfeld Switzerland
Phone: +49 711 78 25 25 21
Email: cschoen@silony-medical.com & info.schweiz@silony-medical.com

SOURCE Silony Medical

LOS ANGELES, Oct. 19, 2023 /PRNewswire/ — Expanding Innovations, Inc. (EI), an emerging technology leader in the expandable interbody cage sector of the spine industry, has announced the full commercial launch of the X-PAC Expandable Lateral Cage System (X-PAC LLIF).

Some of the first procedures using the cage were performed by Dr. Brandon K. Strenge of the Orthopedic Institute of Western Kentucky. Dr. Strenge noted, “The X-PAC Expandable Lateral Cage design incorporates the fundamental lateral interbody fusion principles of indirect decompression and bridging bone fusion. The maximal posterior expansion of X-PAC helps restore foraminal height, facilitating indirect decompression. In addition, the large open architecture and streamlined post-packing instrumentation create an ideal endplate-to-endplate fusion column.”

The launch of X-PAC LLIF represents the first in a series of planned commercial releases aimed at expanding EI’s portfolio of NON-SCREW-based Expandable Cage Technology. The company is actively developing solutions for ALIF, ATP and endoscopic procedures, and is integrating integrated fixation and hyperlordotic options within the LLIF portfolio.

“We are pleased with the positive feedback and adoption rate we observed during our initial market launch, as this is consistent with the success of our flagship product, the X-PAC Expandable Posterior Cage System (X-PAC TLIF). We look forward to the full commercial launch and the growth this means for our company,” said Robert Jaramillo, CEO of Expanding Innovations.

Expanding Innovations, Inc. (EI) has developed a revolutionary, NON-SCREW-based expandable technology that surgeons and patients can count on. The X-PAC Expandable Cage design replaces the traditional inner cage lifting screw with a powerful, continuous expansion mechanism, supported by unidirectional locking teeth, for controlled expansion. The EI portfolio includes the X-PAC expandable posterior and lateral cage systems, as well as the active development of X-PAC ALIF, ATP and ENDO platforms. For more information about Expanding Innovations, please visit www.expandinginnovations.com.

SOURCE Expanding Innovations

The partnership aims to incorporate Aclarion’s Nociscan surgical decision technology into ATEC’s AlphaInformatiX platform to better inform spine surgery

ATEC is a medical device company committed to revolutionizing the approach to spine surgery through clinical differentiation

Aclarion’s Nociscan is the first augmented intelligence platform to measure biomarkers of intervertebral disc health in the lumbar spine, helping doctors identify the location of chronic low back pain

BROOMFIELD, CO, October 23, 2023 (GLOBE NEWSWIRE) – via NewMediaWire —Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that uses biomarkers and proprietary enhanced intelligence algorithms to help physicians identify the location of chronic low back pain, today announced that the company has executed a non-binding Letter of Intent (“LOI”) to to form a strategic partnership with ATEC Spine, Inc., the wholly owned operating subsidiary of Alphatec Holdings, Inc. (Nasdaq: ATEC).

By combining the unique structural data powered by ATEC’s AlphaInformatiX with the innovative biomarker data that allows Aclarion’s Nociscan solution to identify each intervertebral disc as painful or not, surgeons will have unprecedented data on one platform. The platform is designed to improve clinical outcomes while reducing overall procedural costs for patients with chronic back pain.

Pat Miles, CEO of ATEC, commented: “Developing spinal technologies through innovation requires discipline, time, knowledge and resources. This collaboration with Aclarion reflects our belief in the importance of biochemical markers within the treatment paradigm. Nociscan is exactly the kind of innovation that can advance our shared goal of integrating and advancing technologies that improve the predictability and reproducibility of spine care.”

Aclarion’s proprietary decision support tool, Nociscan, is the first evidence-based SaaS platform that helps physicians non-invasively distinguish between painful and non-painful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers shown to be associated with disc pain. Biomarker data is fed into proprietary algorithms to indicate whether a disc may be a source of pain. When combined with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving clinicians clarity to optimize treatment strategies.

Aclarion’s published studies confirm the comparative advantage of Nociscan in achieving differentiated surgical outcomes. In April 2023, Aclarion announced a published, peer-reviewed 85% 2-year success rate for discogenic low back pain surgery in patients whose treatment strategy was consistent with Nociscan-identified discs. This result was a 22 percentage point improvement over patients whose treatment strategy was inconsistent with Nociscan-identified discs (85% vs. 63%; p=0.07).¹

^{1 https://pubmed.ncbi.nlm.nih.gov/37014434/}

“We share a common vision with ATEC on the value of advanced decision support information to improve patient care. This strategic partnership is an important milestone for Aclarion. Pat and the ATEC team are revolutionizing spine surgery, and we appreciate their support,” said Brent Ness, CEO of Aclarion.

The LOI is considering a multi-step strategic partnership. Under the LOI, ATEC and Aclarion will work together to identify Key Opinion Leader (KOL) surgeons who can evaluate the Nociscan technology. Feedback from these surgeons will form the basis for clinical evaluations designed to assess the utility of Nociscan in combination with EOS imaging, the foundation of ATEC’s AlphaInformatiX platform. Based on positive synergies, ATEC and Aclarion will jointly commercialize Nociscan in specific markets. In exchange for selected access to ATEC’s surgeon network for the evaluation and development of Nociscan, Aclarion will grant ATEC certain exclusive distribution rights to include Nociscan as part of an integrated procedural solution.

Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disorders and low back pain. Conventional imaging and diagnostics provide valuable structural information, but are limited in identifying the source of the pathogenic pain.

About Aclarion, Inc.

Aclarion is a healthcare technology company that uses magnetic resonance spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers and enhanced intelligence algorithms to optimize clinical treatments. The company is entering the chronic low back pain market for the first time with Nociscan, the first evidence-based SaaS platform that helps physicians non-invasively distinguish between painful and non-painful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers shown to be associated with disc pain. Biomarker data is fed into proprietary algorithms to indicate whether a disc may be a source of pain. When combined with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving clinicians clarity to optimize treatment strategies. For more information please visit www.aclarion.com.

About ATEC

Alphatec Holdings, Inc. is, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging SA and SafeOp Surgical, Inc., a medical device company committed to revolutionizing the approach to spine surgery through clinical differentiation. ATEC’s organic innovation machine^T.M is focused on developing new approaches that integrate seamlessly with the company’s growing AlphaInformatiX Platform to better inform surgery and achieve the goals of spine surgery more safely and reproducibly. ATEC’s vision is to be the standard bearer in the spine field. For more information visit us at www.atecspine.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on management’s current plans and expectations and are subject to a number of uncertainties and risks that could materially affect the company’s current plans and expectations, as well as its future results of operations and financial condition. These and other risks and uncertainties are discussed in more detail in our filings with the Securities and Exchange Commission. Readers are encouraged to read the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as well as other disclosures in the prospectus and subsequent filings with the Securities and Exchange Commission. . Forward-looking statements in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Revelation

The information above has been prepared by Aclarion and reflects the opinion of Aclarion only. Nothing in this statement should be construed as any endorsement or approval of Aclarion or any of its products by ATEC.

Investor contacts:
Kirin M. Smith
PCG Advice, Inc.
646.823.8656
ksmith@pcgadvisory.com

Media contacts:
Jodi Lamberti
SPRIG advice
612.812.7477
jodi@sprigconsulting.com